STOCK TITAN

[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Hims & Hers Health (HIMS) insider filing: Chief Legal Officer Soleil Boughton reported a sale of Class A Common Stock on 10/27/2025. The Form 4 lists a sale of 2,637 shares at a price of $50.10 per share, coded “S.” Following the transaction, the reporting person beneficially owns 158,493 shares, held directly.

The filing notes the trades were effected under a Rule 10b5-1 trading plan adopted on August 28, 2024. This disclosure reflects personal share transactions by an officer and does not describe company operating results.

Hims & Hers Health (HIMS) deposito di informazioni per insider: il Chief Legal Officer Soleil Boughton ha riferito una vendita di azioni ordinarie di Classe A il 27/10/2025. Il Modulo 4 elenca una vendita di 2.637 azioni al prezzo di $50,10 per azione, codificata come “S.” Dopo la transazione, il soggetto segnalante detiene beneficialmente 158.493 azioni, detenute direttamente.

Il deposito indica che le operazioni sono state effettuate nell’ambito di un piano di negoziazione Rule 10b5-1 adottato il 28 agosto 2024. Questa divulgazione riflette operazioni personali di azioni da parte di un dirigente e non descrive i risultati operativi della società.

Hims & Hers Health (HIMS) presentación de insider: la Directora Jurídica Soleil Boughton reportó la venta de acciones ordinarias de Clase A el 27/10/2025. El Formulario 4 lista una venta de 2.637 acciones a un precio de $50.10 por acción, codificada como “S.” Tras la operación, la persona reportante posee Beneficialmente 158.493 acciones, en forma directa.

La presentación señala que las operaciones se realizaron bajo un plan de negociación Rule 10b5-1 adoptado el 28 de agosto de 2024. Esta divulgación refleja transacciones de acciones personales de un ejecutivo y no describe los resultados operativos de la compañía.

Hims & Hers Health (HIMS) 내부자 공시: 최고법무책임자 Soleil Boughton이 2025년 10월 27일에 보통주 1 Classe A 주식 매도를 보고했습니다. Form 4에 2,637주의 매도가 주당 $50.10으로 기재되어 있으며, 코딩은 “S”입니다. 이 거래 후 보고자는 직접 보유하고 있는 158,493주를 실질적으로 소유합니다.

공시는 이 거래가 2024년 8월 28일에 채택된 Rule 10b5-1 거래 계획에 따라 실행되었다고 적고 있습니다. 이 공시는 임원의 개인 주식 거래를 반영하며 회사의 운영 결과를 설명하지 않습니다.

Hims & Hers Health (HIMS) divulgation d'informations privilégiées: le Chief Legal Officer Soleil Boughton a signalé une vente d’actions ordinaires de classe A le 27/10/2025. Le Formulaire 4 répertorie une vente de 2 637 actions au prix de $50,10 par action, codée “S”. Suite à la transaction, la personne déclarant détient 158 493 actions de façon bénéficiaire, détenues directement.

Le dépôt indique que les transactions ont été effectuées dans le cadre d’un plan de négociation Rule 10b5-1 adopté le 28 août 2024. Cette divulgation reflète des transactions personnelles d’actions par un dirigeant et ne décrit pas les résultats opérationnels de l’entreprise.

Hims & Hers Health (HIMS) Insider-Filing: Chief Legal Officer Soleil Boughton berichtete einen Verkauf von Class-A-Stammaktien am 27.10.2025. Das Formular 4 listet einen Verkauf von 2.637 Aktien zu einem Preis von $50,10 pro Aktie, codiert mit “S.” Nach der Transaktion besitzt die meldepflichtige Person vorteilhaft 158.493 Aktien, direkt gehalten.

Im Bericht wird vermerkt, dass die Geschäfte im Rahmen eines Rule 10b5-1-Handelsplans durchgeführt wurden, der am 28. August 2024 angenommen wurde. Diese Offenlegung spiegelt persönliche Aktiengeschäfte eines Mitarbeiters wider und beschreibt keine operativen Ergebnisse des Unternehmens.

Hims & Hers Health (HIMS) إفصاح داخلي: ذكرت مسؤولة الشؤون القانونية الرئيسية سوليل بوطن بيع أسهم عادية من الفئة أ في 27/10/2025. يسرد النموذج 4 بيع 2,637 سهماً بسعر $50.10 للسهم، مُرمّز بـ “S.” عقب الصفقة، يملك الشخص المبلغ عنه فعلياً 158,493 سهماً، مملوكة بشكل مباشر.

تشير الإفادة إلى أن التداولات تم تنفيذها بموجب خطة تداول Rule 10b5-1 المعتمدة في 28 أغسطس 2024. هذا الكشف يعكس معاملات أسهم شخصية لمسؤول ولا يصف نتائج تشغيل الشركة.

Positive
  • None.
Negative
  • None.

Hims & Hers Health (HIMS) deposito di informazioni per insider: il Chief Legal Officer Soleil Boughton ha riferito una vendita di azioni ordinarie di Classe A il 27/10/2025. Il Modulo 4 elenca una vendita di 2.637 azioni al prezzo di $50,10 per azione, codificata come “S.” Dopo la transazione, il soggetto segnalante detiene beneficialmente 158.493 azioni, detenute direttamente.

Il deposito indica che le operazioni sono state effettuate nell’ambito di un piano di negoziazione Rule 10b5-1 adottato il 28 agosto 2024. Questa divulgazione riflette operazioni personali di azioni da parte di un dirigente e non descrive i risultati operativi della società.

Hims & Hers Health (HIMS) presentación de insider: la Directora Jurídica Soleil Boughton reportó la venta de acciones ordinarias de Clase A el 27/10/2025. El Formulario 4 lista una venta de 2.637 acciones a un precio de $50.10 por acción, codificada como “S.” Tras la operación, la persona reportante posee Beneficialmente 158.493 acciones, en forma directa.

La presentación señala que las operaciones se realizaron bajo un plan de negociación Rule 10b5-1 adoptado el 28 de agosto de 2024. Esta divulgación refleja transacciones de acciones personales de un ejecutivo y no describe los resultados operativos de la compañía.

Hims & Hers Health (HIMS) 내부자 공시: 최고법무책임자 Soleil Boughton이 2025년 10월 27일에 보통주 1 Classe A 주식 매도를 보고했습니다. Form 4에 2,637주의 매도가 주당 $50.10으로 기재되어 있으며, 코딩은 “S”입니다. 이 거래 후 보고자는 직접 보유하고 있는 158,493주를 실질적으로 소유합니다.

공시는 이 거래가 2024년 8월 28일에 채택된 Rule 10b5-1 거래 계획에 따라 실행되었다고 적고 있습니다. 이 공시는 임원의 개인 주식 거래를 반영하며 회사의 운영 결과를 설명하지 않습니다.

Hims & Hers Health (HIMS) divulgation d'informations privilégiées: le Chief Legal Officer Soleil Boughton a signalé une vente d’actions ordinaires de classe A le 27/10/2025. Le Formulaire 4 répertorie une vente de 2 637 actions au prix de $50,10 par action, codée “S”. Suite à la transaction, la personne déclarant détient 158 493 actions de façon bénéficiaire, détenues directement.

Le dépôt indique que les transactions ont été effectuées dans le cadre d’un plan de négociation Rule 10b5-1 adopté le 28 août 2024. Cette divulgation reflète des transactions personnelles d’actions par un dirigeant et ne décrit pas les résultats opérationnels de l’entreprise.

Hims & Hers Health (HIMS) Insider-Filing: Chief Legal Officer Soleil Boughton berichtete einen Verkauf von Class-A-Stammaktien am 27.10.2025. Das Formular 4 listet einen Verkauf von 2.637 Aktien zu einem Preis von $50,10 pro Aktie, codiert mit “S.” Nach der Transaktion besitzt die meldepflichtige Person vorteilhaft 158.493 Aktien, direkt gehalten.

Im Bericht wird vermerkt, dass die Geschäfte im Rahmen eines Rule 10b5-1-Handelsplans durchgeführt wurden, der am 28. August 2024 angenommen wurde. Diese Offenlegung spiegelt persönliche Aktiengeschäfte eines Mitarbeiters wider und beschreibt keine operativen Ergebnisse des Unternehmens.

Hims & Hers Health (HIMS) إفصاح داخلي: ذكرت مسؤولة الشؤون القانونية الرئيسية سوليل بوطن بيع أسهم عادية من الفئة أ في 27/10/2025. يسرد النموذج 4 بيع 2,637 سهماً بسعر $50.10 للسهم، مُرمّز بـ “S.” عقب الصفقة، يملك الشخص المبلغ عنه فعلياً 158,493 سهماً، مملوكة بشكل مباشر.

تشير الإفادة إلى أن التداولات تم تنفيذها بموجب خطة تداول Rule 10b5-1 المعتمدة في 28 أغسطس 2024. هذا الكشف يعكس معاملات أسهم شخصية لمسؤول ولا يصف نتائج تشغيل الشركة.

Hims & Hers Health (HIMS) 内部人备案:首席法务官 Soleil Boughton 报告于 2025/10/27 出售了A类普通股。Form 4 列出以每股 $50.10 的价格出售 2,637 股,代码为“ S ”。交易后,该披露人实际拥有直接持有的 158,493 股

备案指出该交易是在 2024年8月28日 通过 Rule 10b5-1 交易计划 实施的。本披露反映了高管个人股票交易,并不描述公司的经营业绩。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Boughton Soleil

(Last) (First) (Middle)
2269 CHESTNUT STREET, #523

(Street)
SAN FRANCISCO CA 94123

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/27/2025 S(1) 2,637 D $50.1 158,493 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
Remarks:
/s/ Kimberly Mather, Attorney-in-Fact for Soleil Boughton 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

HIMS Latest News

HIMS Latest SEC Filings

HIMS Stock Data

10.90B
202.99M
10.63%
88.99%
33.02%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO